Xenetic Biosciences Inc
xeneticbio.comWhat Do They Do?
Develops DNase-based therapies intended to support cancer treatments for patients with pancreatic and other solid tumors, and licenses drug-delivery technology to pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our…View ↗
We are focused on advancing the development of our DNase technology toward a first-in-human, multicenter, dose escalation and…View ↗
We have partnered with biotechnology and pharmaceutical companies to develop our proprietary drug delivery platform, PolyXen, and receive…View ↗
How Do They Make Money?
Pharmaceutical and biotechnology partners pay for licenses through upfront fees and development or regulatory milestones; Xenetic can also receive royalties on partner product sales and reimbursement for research work. Royalties follow partner sales, while upfront and milestone payments tied to ongoing work are spread across the work period.
10-K for FY2025, filed Mar 12, 2026The Company enters into supply, license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which…View ↗
The terms of the Company’s license agreements may include delivery of an intellectual property license to a collaboration partner. The…View ↗
The Company expects to recognize royalty revenue in the period of sale, based on the underlying contract terms, provided that the reported…View ↗
$3M
-
10-K for FY2025, filed Mar 12, 2026
$3M ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies work with Xenetic through supply, license and collaboration arrangements; Serum Institute has an exclusive license to use PolyXen to develop a potential product.
10-K for FY2025, filed Mar 12, 2026
Do Revenues Turn Into Profits?
No. It lost $2.7M in FY2025.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$929.7KView ↗
- ▲ +35% (Loss)
- vs −$688.7K in Q2 FY2025
-
Sep 14, 2026
Agreed to acquire Santersus in an all-stock share exchange
The proposed acquisition would combine Xenetic with Santersus through newly issued Xenetic shares and requires stockholder approval.
Sources
8-K, filed Sep 16, 2026
On September 14, 2026, Xenetic Biosciences, Inc., a Nevada corporation (“Xenetic” or the “Company”), entered into a Share Exchange…View ↗
Growing. Revenue grew 2.6x in 4 years, from $1.2M in FY2021 to $3M in FY2025, about 27% a year.
Narrower research focus
The older report described internal development of both DNase and XCART, while the latest report identifies DNase as the focus of internal efforts; XCART development had been suspended as resources were prioritized for DNase.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 12, 2026We incorporate our patented and proprietary technologies into drug candidates currently under development with biotechnology and…View ↗
Who Do They Compete With?
Competes with Merck
10-K for FY2025, filed Mar 12, 2026In the field of pancreatic cancer, we will compete with the few, currently approved treatments for pancreatic carcinoma, including…View ↗
Loading...
